Daxor (DXR) Competitors $11.34 +0.49 (+4.52%) As of 03:07 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DXR vs. INGN, INFU, KRMD, MGRM, CV, TLSI, CVRX, BSGM, ELMD, and LNSRShould you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Inogen (INGN), InfuSystem (INFU), KORU Medical Systems (KRMD), Monogram Orthopaedics (MGRM), CapsoVision (CV), TriSalus Life Sciences (TLSI), CVRx (CVRX), Biosig Technologies (BSGM), Electromed (ELMD), and LENSAR (LNSR). These companies are all part of the "medical equipment" industry. Daxor vs. Its Competitors Inogen InfuSystem KORU Medical Systems Monogram Orthopaedics CapsoVision TriSalus Life Sciences CVRx Biosig Technologies Electromed LENSAR Daxor (NASDAQ:DXR) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Which has higher valuation & earnings, DXR or INGN? Daxor has higher earnings, but lower revenue than Inogen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaxorN/AN/AN/AN/AN/AInogen$343.47M0.62-$35.89M-$1.06-7.48 Is DXR or INGN more profitable? Daxor has a net margin of 0.00% compared to Inogen's net margin of -7.58%. Daxor's return on equity of 0.00% beat Inogen's return on equity.Company Net Margins Return on Equity Return on Assets DaxorN/A N/A N/A Inogen -7.58%-13.77%-8.52% Do analysts prefer DXR or INGN? Daxor presently has a consensus target price of $25.00, indicating a potential upside of 120.46%. Inogen has a consensus target price of $11.00, indicating a potential upside of 38.71%. Given Daxor's stronger consensus rating and higher possible upside, equities analysts plainly believe Daxor is more favorable than Inogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Inogen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals & insiders have more ownership in DXR or INGN? 1.3% of Daxor shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 59.5% of Daxor shares are owned by company insiders. Comparatively, 1.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer DXR or INGN? In the previous week, Daxor and Daxor both had 1 articles in the media. Daxor's average media sentiment score of 1.91 beat Inogen's score of 1.33 indicating that Daxor is being referred to more favorably in the media. Company Overall Sentiment Daxor Very Positive Inogen Positive Which has more risk and volatility, DXR or INGN? Daxor has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. SummaryDaxor beats Inogen on 7 of the 10 factors compared between the two stocks. Get Daxor News Delivered to You Automatically Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXR vs. The Competition Export to ExcelMetricDaxorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.89M$4.13B$5.74B$9.78BDividend YieldN/A1.25%4.40%4.04%P/E RatioN/A27.1130.8326.39Price / SalesN/A25.06382.9086.63Price / CashN/A26.7037.7259.11Price / BookN/A2.9110.106.62Net IncomeN/A$189.47M$3.26B$265.42M7 Day Performance6.18%2.70%3.90%3.58%1 Month Performance11.83%15.89%3.73%0.46%1 Year Performance41.75%17.16%37.68%19.41% Daxor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRDaxor4.3247 of 5 stars$11.34+4.5%$25.00+120.5%+26.5%$54.89MN/A0.0037Gap DownINGNInogen4.3408 of 5 stars$7.49-0.8%$11.00+46.9%-37.2%$204.15M$335.70M-7.071,030Positive NewsINFUInfuSystem2.5762 of 5 stars$9.62+0.9%$12.50+29.9%+54.8%$194.66M$139.89M160.36410KRMDKORU Medical Systems1.2782 of 5 stars$4.12-2.1%$4.63+12.3%+82.1%$194.65M$33.65M-45.7880MGRMMonogram Orthopaedics1.9232 of 5 stars$5.29-0.6%$5.40+2.1%+73.0%$189.86M$370K-10.5828CVCapsoVisionN/A$3.89-2.8%$5.50+41.4%N/A$187.10MN/A0.0090TLSITriSalus Life Sciences3.0667 of 5 stars$4.65-4.3%$10.75+131.2%-11.8%$183.90M$29.43M-3.94106CVRXCVRx2.4851 of 5 stars$7.25+5.5%$14.00+93.1%-24.2%$179.66M$51.29M-3.45160Positive NewsBSGMBiosig Technologies2.4145 of 5 stars$4.81-12.2%$10.00+107.9%+1,077.7%$172.18M$40K0.0050Positive NewsELMDElectromed2.3178 of 5 stars$19.16-2.7%$33.50+74.8%+36.4%$160.68M$61.44M25.55160News CoverageAnalyst ForecastLNSRLENSAR1.0446 of 5 stars$12.50-2.0%$15.00+20.0%+176.7%$152.17M$58.36M-2.97110News Coverage Related Companies and Tools Related Companies Inogen Alternatives InfuSystem Alternatives KORU Medical Systems Alternatives Monogram Orthopaedics Alternatives CapsoVision Alternatives TriSalus Life Sciences Alternatives CVRx Alternatives Biosig Technologies Alternatives Electromed Alternatives LENSAR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXR) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access